Tags

Type your tag names separated by a space and hit enter

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.

Abstract

OBJECTIVE

To investigate the combined effect of diet and orlistat, for 24 weeks, on anthropometric features, hormonal parameters, and indices of insulin resistance in obese women with polycystic ovary syndrome (PCOS) and in obese women without the syndrome.

DESIGN

Prospective clinical study.

SETTING

Department of obstetrics and gynecology in a major university in Greece.

PATIENT(S)

Eighteen selected women with PCOS were matched for age and body mass index with 14 obese control women.

INTERVENTION(S)

Subjects were prescribed an energy-restricted diet, and orlistat (120 mg, 3 times per d) was administered to all subjects for 24 weeks.

MAIN OUTCOME MEASURE(S)

At baseline, week 12, and week 24, after an overnight fast, blood samples were collected, and serum levels of FSH, LH, PRL, T, Delta(4)A, DHEAS, 17 alpha-hydroxyprogesterone, sex hormone-binding globulin, glucose, and insulin were measured.

RESULT(S)

Testosterone levels were significantly decreased with treatment in women with PCOS; this decrease was attributed to the first trimester, whereas T levels did not change during the second 12-week period. In women with PCOS, insulin levels and HOMA-IR values were decreased during the first 12 weeks, whereas no significant change was observed during the second trimester.

CONCLUSION(S)

Orlistat administration, combined with diet, for 24 weeks, resulted in significant weight loss and improvement of insulin resistance in obese women, with or without PCOS. Moreover, T levels were significantly decreased in women with PCOS. There appears to be a trend during the first 12-week period for greater improvement of metabolic and hormonal parameters in women with PCOS.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    2nd Department of Obstetrics and Gynecology, Division of Human Reproduction, Aristotle University of Thessaloniki, Thessaloniki, Greece.

    , , , ,

    Source

    Fertility and sterility 89:4 2008 Apr pg 899-906

    MeSH

    17-alpha-Hydroxyprogesterone
    Androgens
    Androstenedione
    Anti-Obesity Agents
    Blood Glucose
    Body Mass Index
    Caloric Restriction
    Case-Control Studies
    Combined Modality Therapy
    Dehydroepiandrosterone Sulfate
    Female
    Follicle Stimulating Hormone
    Humans
    Insulin
    Insulin Resistance
    Lactones
    Luteinizing Hormone
    Obesity
    Orlistat
    Polycystic Ovary Syndrome
    Prolactin
    Prospective Studies
    Sex Hormone-Binding Globulin
    Testosterone
    Time Factors
    Treatment Outcome
    Weight Loss

    Pub Type(s)

    Controlled Clinical Trial
    Journal Article

    Language

    eng

    PubMed ID

    17980364

    Citation

    Panidis, Dimitrios, et al. "Obesity, Weight Loss, and the Polycystic Ovary Syndrome: Effect of Treatment With Diet and Orlistat for 24 Weeks On Insulin Resistance and Androgen Levels." Fertility and Sterility, vol. 89, no. 4, 2008, pp. 899-906.
    Panidis D, Farmakiotis D, Rousso D, et al. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertil Steril. 2008;89(4):899-906.
    Panidis, D., Farmakiotis, D., Rousso, D., Kourtis, A., Katsikis, I., & Krassas, G. (2008). Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertility and Sterility, 89(4), pp. 899-906.
    Panidis D, et al. Obesity, Weight Loss, and the Polycystic Ovary Syndrome: Effect of Treatment With Diet and Orlistat for 24 Weeks On Insulin Resistance and Androgen Levels. Fertil Steril. 2008;89(4):899-906. PubMed PMID: 17980364.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. AU - Panidis,Dimitrios, AU - Farmakiotis,Dimitrios, AU - Rousso,David, AU - Kourtis,Anargyros, AU - Katsikis,Ilias, AU - Krassas,Gerassimos, Y1 - 2007/11/05/ PY - 2006/11/22/received PY - 2007/04/17/revised PY - 2007/04/17/accepted PY - 2007/11/6/pubmed PY - 2008/4/30/medline PY - 2007/11/6/entrez SP - 899 EP - 906 JF - Fertility and sterility JO - Fertil. Steril. VL - 89 IS - 4 N2 - OBJECTIVE: To investigate the combined effect of diet and orlistat, for 24 weeks, on anthropometric features, hormonal parameters, and indices of insulin resistance in obese women with polycystic ovary syndrome (PCOS) and in obese women without the syndrome. DESIGN: Prospective clinical study. SETTING: Department of obstetrics and gynecology in a major university in Greece. PATIENT(S): Eighteen selected women with PCOS were matched for age and body mass index with 14 obese control women. INTERVENTION(S): Subjects were prescribed an energy-restricted diet, and orlistat (120 mg, 3 times per d) was administered to all subjects for 24 weeks. MAIN OUTCOME MEASURE(S): At baseline, week 12, and week 24, after an overnight fast, blood samples were collected, and serum levels of FSH, LH, PRL, T, Delta(4)A, DHEAS, 17 alpha-hydroxyprogesterone, sex hormone-binding globulin, glucose, and insulin were measured. RESULT(S): Testosterone levels were significantly decreased with treatment in women with PCOS; this decrease was attributed to the first trimester, whereas T levels did not change during the second 12-week period. In women with PCOS, insulin levels and HOMA-IR values were decreased during the first 12 weeks, whereas no significant change was observed during the second trimester. CONCLUSION(S): Orlistat administration, combined with diet, for 24 weeks, resulted in significant weight loss and improvement of insulin resistance in obese women, with or without PCOS. Moreover, T levels were significantly decreased in women with PCOS. There appears to be a trend during the first 12-week period for greater improvement of metabolic and hormonal parameters in women with PCOS. SN - 1556-5653 UR - https://www.unboundmedicine.com/medline/citation/17980364/Obesity_weight_loss_and_the_polycystic_ovary_syndrome:_effect_of_treatment_with_diet_and_orlistat_for_24_weeks_on_insulin_resistance_and_androgen_levels_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015-0282(07)01007-2 DB - PRIME DP - Unbound Medicine ER -